{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:34:42Z","timestamp":1740173682475,"version":"3.37.3"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The pharmacokinetics of temozolomide (TMZ) in patients with severe renal impairments (creatinine clearance, &amp;lt;36 mL\/min\/m2) or in hemodialysis (HD) patients has not been investigated. TMZ and its metabolic products are mainly excreted in urine, as retention of these in the body may result in increased adverse events in HD patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Seven HD patients with high-grade gliomas from 6 institutions were included in the study. Patient characteristics, treatment schedule, clinical course, pathological\/molecular findings, and adverse events were evaluated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The histopathological diagnoses were isocitrate dehydrogenase (IDH) wild-type glioblastoma in 4 cases, not other specified (NOS) glioblastoma in 2 cases, and IDH-mutant anaplastic astrocytoma in 1 case. Five of the 7 patients completed radiotherapy (48-60 Gy) with concomitant TMZ (75 mg\/m2) followed by adjuvant 5-day TMZ (150 mg\/m2) every 28 days. During the entire course of treatment with TMZ, severe (Common Terminology Criteria for Adverse Events [CTCAE] \u2265 Grade 3) lymphocytopenia occurred in 57%, neutropenia in 0%, and thrombocytopenia in 14% of the patients. Generally, the frequency and degree of myelosuppression do not increase in HD patients with high-grade gliomas. Two of the 7 (28.5%) patients died of infectious disease despite having no direct correlation to myelosuppression; that is similar to the death rate of 21.9% resulting from infection in HD patients in Japan.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Decreasing the dose of TMZ might not be required in HD patients with high-grade gliomas during concomitant radiochemotherapy and maintenance therapy. However, careful clinical and hematological observation is required to avoid critical hematotoxicity and infection.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/nop\/npz034","type":"journal-article","created":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T08:20:48Z","timestamp":1575361248000},"page":"111-117","source":"Crossref","is-referenced-by-count":2,"title":["Temozolomide radiochemotherapy for high-grade glioma patients with hemodialysis: a case series of 7 patients"],"prefix":"10.1093","volume":"7","author":[{"given":"Jun","family":"Muto","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Fujita Health University, Japan"},{"name":"Department of Neurosurgery, Keio University School of Medicine, Japan"},{"name":"Department of Neurosurgery, Saiseikai Utsunomiya Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoo","family":"Matsutani","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Chiba University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Matsuda","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Nara Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Kinoshita","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Kanazawa University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuteru","family":"Oikawa","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Nakamura Memorial Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1652-9844","authenticated-orcid":false,"given":"Johan","family":"Pallud","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Sainte-Anne Hospital, Paris, France"},{"name":"Paris Descartes University, Sorbonne Paris Cit\u00e9, France"},{"name":"Inserm, U894, IMA-Brain, Centre de Psychiatrie et Neurosciences, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hikaru","family":"Sasaki","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Keio University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,12,3]]},"reference":[{"issue":"10","key":"2020033012050858500_CIT0001","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med."},{"first-page":"1","volume-title":"Highlight of Prescribing Information: Temozolomide","year":"2017","key":"2020033012050858500_CIT0002"},{"issue":"2","key":"2020033012050858500_CIT0003","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/bjc.1992.57","article-title":"Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)","volume":"65","author":"Newlands","year":"1992","journal-title":"Br J Cancer."},{"issue":"1","key":"2020033012050858500_CIT0004","first-page":"17","article-title":"Experience with temozolomide for two patients with malignant glioma","volume":"22","author":"Oikawa","year":"2011","journal-title":"J Hokkaido Brain Res Found"},{"issue":"4","key":"2020033012050858500_CIT0005","first-page":"671","article-title":"Malignant tumor\u2014how to use the medication for hemodialysis patients","volume":"70","author":"Okamoto","year":"2011","journal-title":"Jin to T\u014dseki [Kidney and Dialysis]."},{"issue":"6","key":"2020033012050858500_CIT0006","first-page":"1101","article-title":"Molecular characteristics of pediatric non-ependymal, non-pilocytic gliomas associated with resistance to temozolomide","volume":"4","author":"Ezaki","year":"2011","journal-title":"Mol Med Rep."},{"issue":"5","key":"2020033012050858500_CIT0007","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10147-007-0687-5","article-title":"Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians","volume":"12","author":"Aoki","year":"2007","journal-title":"Int J Clin Oncol."},{"issue":"8","key":"2020033012050858500_CIT0014","doi-asserted-by":"crossref","first-page":"471","DOI":"10.5649\/jjphcs.38.471","article-title":"Risk analysis of lymphocytopenia with temozolomide radiochemotherapy","volume":"38","author":"Kobayashi","year":"2012","journal-title":"Iryo Yakugaku [Japanese Journal of Pharmaceutical Health Care and Sciences]"},{"issue":"8","key":"2020033012050858500_CIT0008","doi-asserted-by":"crossref","first-page":"638","DOI":"10.2176\/nmc.50.638","article-title":"Low peripheral lymphocyte count before focal radiotherapy plus concomitant temozolomide predicts severe lymphopenia during malignant glioma treatment","volume":"50","author":"Ishikawa","year":"2010","journal-title":"Neurol Med Chir (Tokyo)."},{"issue":"5","key":"2020033012050858500_CIT0015","first-page":"545","article-title":"Analysis of factors influencing thrombocytopenia associated with concomitant temozolomide and radiotherapy","volume":"51","author":"Ichie","year":"2015","journal-title":"Nichibyoshi"},{"issue":"3","key":"2020033012050858500_CIT0016","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2165\/00003088-198106030-00002","article-title":"Nomograms for drug use in renal disease","volume":"6","author":"Chennavasin","year":"1981","journal-title":"Clin Pharmacokinet."},{"issue":"3","key":"2020033012050858500_CIT0009","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00066-005-1314-x","article-title":"Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma","volume":"181","author":"Kocher","year":"2005","journal-title":"Strahlenther Onkol."},{"issue":"9","key":"2020033012050858500_CIT0010","first-page":"1279","article-title":"Efficacy and safety of monotherapy with temozolomide in patients with anaplastic astrocytoma at first relapse\u2014a phase II clinical study [article in Japanese]","volume":"33","author":"Nishikawa","year":"2006","journal-title":"Gan To Kagaku Ryoho [Jpn J Cancer Chemother]"},{"issue":"23","key":"2020033012050858500_CIT0011","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1200\/JCO.2008.20.7944","article-title":"Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma","volume":"27","author":"Clarke","year":"2009","journal-title":"J Clin Oncol."},{"issue":"7","key":"2020033012050858500_CIT0012","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(12)70164-X","article-title":"Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial","volume":"13","author":"Wick","year":"2012","journal-title":"Lancet Oncol."},{"key":"2020033012050858500_CIT0013","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1200\/jco.2011.29.15_suppl.2006","article-title":"RTOG 0525: a randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM)","volume":"29","author":"Gilbert","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Neuro-Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/nop\/article-pdf\/7\/1\/111\/32980818\/npz034.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/nop\/article-pdf\/7\/1\/111\/32980818\/npz034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T16:05:56Z","timestamp":1585584356000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nop\/article\/7\/1\/111\/5650811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,3]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12,3]]},"published-print":{"date-parts":[[2020,1,31]]}},"URL":"https:\/\/doi.org\/10.1093\/nop\/npz034","relation":{},"ISSN":["2054-2577","2054-2585"],"issn-type":[{"type":"print","value":"2054-2577"},{"type":"electronic","value":"2054-2585"}],"subject":[],"published-other":{"date-parts":[[2020,2,1]]},"published":{"date-parts":[[2019,12,3]]}}}